The current strategic research agenda (SRA) draft will be further developed according to the input and outcomes of the May 27-28 Geneva invitational conference. The resulting new draft will be made available to the public at this website no later than September 1, 2013. The research and stakeholder communities are most welcome to comment the SRA at this time.
The JPIAMR Invitational Conference to discuss the strategic research agenda (SRA) was held in Geneva on May 27 and 28. Members from the management board, scientific advisory board and stakeholder advisory board, as well as additional experts, met for group and plenary discussions.
The constructive discussions have provided the SRA writers with a wealth of additional input to incorporate into the next SRA draft. We would like to thank all meeting participants for a productive conference!
An invitational conference will be held in Geneva on May 27-28.The main discussion topic will be the latest draft of the strategic research agenda (SRA). All members of the management board, the scientific advisory board and the stakeholder advisory board are invited, along with some additional experts.
Stakeholder involvement will be crucial for the process of first developing and then implementing a strategic research agenda (SRA). A first stakeholder advisory board (SHAB) meeting was held at the Romanian Office for Science and Technology in Brussels on April 18 with representatives from Action on Antibiotic Resistance (ReACT), European Federation of Pharmaceutical Industries Associations (EFPIA), Federation of European Microbiological Societies (FEMS), Federation of Veterinarians of Europe (FVE), Standing Committee of European Doctors, and WHO Europe. The primary discussion topic was the recent SRA draft. Members of the SHAB will also participate in the upcoming JPIAMR invitational conference in Geneva.
In the February issue of The Lancet Infectious Diseases Herman Goossens, chairman of JPIAMR’s scientific advisory board, comments on “The Chennai Declaration—a roadmap to tackle the challenges of antimicrobial resistance in India”.
The Innovative Medicins Initiative (IMI) launched its 8th call for proposals.Topics included under the IMI programme “Combating Antibiotic Resistance: New Drugs for Bad Bugs” are:
- Topic 1C: Innovative Trial Design & Clinical Development
- Topic 3: Discovery and development of new drugs combating Gram – negative infections
Dealine for submitting a proposal is 19 March 2013.
About the Innovative Medicins Initiative:
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
The Swedish government allocates a total of SEK 265 million over four years for research on infection and antibiotics. The initiative was announced in the Research and Innovation bill of 2013, outlining the Swedish government’s research policy and funding for 2013-2016.
In the bill, the Swedish government further states that:
“To strengthen the international competitiveness of Swedish research, the Government has used the following starting points for the assessments made in the bill:
• freedom, long-term approach and greater opportunities for risk-taking;
• greater possibilities to achieve high quality;
• good conditions for researchers;
• initiatives for society and business; and
• increased utilisation of research-based knowledge.”
A two-day conference on the results and experience coming from joint programming activities to date will take place in Dublin February 28–March 1, 2013. The conference is organised within the realms of the Irish presidency and is excpected to attract 300-500 participants. Conclusions drawn from the conference will be used to progress the ERA and the H2020 agendas.